A baby born with a rare, life-threatening genetic disorder is thriving after receiving a groundbreaking, personalised gene-editing treatment.
The experimental therapy, crafted specifically for his condition, corrected a minute yet crucial error in his genetic code, offering hope for others with similarly rare diseases.
The infant, KJ Muldoon of Clifton Heights, Pennsylvania, was diagnosed shortly after birth with severe CPS1 deficiency.
This condition, estimated to affect roughly one in a million babies, prevents the body from effectively removing ammonia, leading to potentially toxic buildup in the bloodstream.
While liver transplants can be a solution for some, this innovative gene-editing treatment offers a new avenue of hope.
The study, published in the New England Journal of Medicine, details KJ’s case and highlights the potential of this technology.
Dr. Kiran Musunuru, a University of Pennsylvania gene editing expert and study co-author, hailed the treatment as “the first step towards the use of gene editing therapies to treat a wide variety of rare genetic disorders for which there are currently no definitive medical treatments.”
KJ’s case represents a significant advancement in personalised medicine, demonstrating the potential to tailor treatments to individual genetic profiles.
While widespread availability of such personalised therapies remains on the horizon, this success story offers a beacon of hope for the millions affected by rare genetic conditions often overlooked by mainstream medical advancements.
KJ is among the first to benefit from this cutting-edge approach, paving the way for future applications of gene editing in treating a broader spectrum of rare diseases.
Knowing KJ’s odds, parents Kyle and Nicole Muldoon, both 34, worried they could lose him.
“We were, like, you know, weighing all the options, asking all the questions for either the liver transplant, which is invasive, or something that’s never been done before,” Nicole said.
“We prayed, we talked to people, we gathered information, and we eventually decided that this was the way we were going to go,” her husband added.
Within six months, the team at Children’s Hospital of Philadelphia and Penn Medicine, along with their partners, created a therapy designed to correct KJ’s faulty gene. They used CRISPR, the gene editing tool that won its inventors the Nobel Prize in 2020. Instead of cutting the DNA strand like the first CRISPR approaches, doctors employed a technique that flips the mutated DNA “letter” — also known as a base — to the correct type. Known as “base editing,” it reduces the risk of unintended genetic changes.
It’s “very exciting” that the team created the therapy so quickly, said gene therapy researcher Senthil Bhoopalan at St. Jude Children’s Research Hospital in Memphis, who wasn’t involved in the study. “This really sets the pace and the benchmark for such approaches.”
In February, KJ got his first IV infusion with the gene editing therapy, delivered through tiny fatty droplets called lipid nanoparticles that are taken up by liver cells.
While the room was abuzz with excitement that day, “he slept through the entire thing,” recalled study author Dr. Rebecca Ahrens-Nicklas, a gene therapy expert at CHOP.
After follow-up doses in March and April, KJ has been able to eat more normally and has recovered well from illnesses like colds, which can strain the body and exacerbate symptoms of CPS1. The 9 ½-month old also takes less medication.
Considering his poor prognosis earlier, “any time we see even the smallest milestone that he’s meeting – like a little wave or rolling over – that’s a big moment for us,” his mother said.
Still, researchers caution that it’s only been a few months. They’ll need to watch him for years.
“We’re still very much in the early stages of understanding what this medication may have done for KJ,” Ahrens-Nicklas said. “But every day, he’s showing us signs that he’s growing and thriving.”
Researchers hope what they learn from KJ will help other rare disease patients.
Gene therapies, which can be extremely expensive to develop, generally target more common disorders in part for simple financial reasons: more patients mean potentially more sales, which can help pay the development costs and generate more profit. The first CRISPR therapy approved by the U.S. Food and Drug Administration, for example, treats sickle cell disease, a painful blood disorder affecting millions worldwide.
Musunuru said his team’s work — funded in part by the National Institutes of Health — showed that creating a custom treatment doesn’t have to be prohibitively expensive. The cost was “not far off” from the $800,000-plus for an average liver transplant and related care, he said.
“As we get better and better at making these therapies and shorten the time frame even more, economies of scale will kick in and I would expect the costs to come down,” Musunuru said.
Scientists also won’t have to redo all the initial work every time they create a customised therapy, Bhoopalan said, so this research “sets the stage” for treating other rare conditions.
Carlos Moraes, a neurology professor at the University of Miami who wasn’t involved with the study, said research like this opens the door to more advances.
“Once someone comes with a breakthrough like this, it will take no time” for other teams to apply the lessons and move forward, he said. “There are barriers, but I predict that they are going to be crossed in the next five to 10 years. Then the whole field will move as a block because we’re pretty much ready.”
